Isatuximab (Isatuximab) price, specifications and purchase channels

Isatuximab is a monoclonal antibody drug targeting CD38 and is mainly used to treat patients with multiple myeloma. By targeting CD38, isatuximab can exert anti-tumor effects, including inducing tumor cell apoptosis and activating the immune system, thereby clinically improving patient outcomes. The drug provides a new treatment option for advanced and relapsed myeloma.

In terms of dosage specifications, isatuximab is usually an intravenous injection preparation. The common specifications are 100mg/ bottles or similar dosages. The specific dosage plan needs to be formulated based on the patient's body surface area and the doctor's evaluation results. Combination regimens are often used clinically, such as with drugs such as lenalidomide or dexamethasone, to improve treatment efficacy and delay disease progression. The dosage and cycle of medication need to be strictly followed by the doctor's instructions.

In terms of price, isatuximab has been launched in the country and has been included in medical insurance reimbursement items. The domestic market price is approximately more than 12,000 yuan per bottle. The overseas version is more expensive, about over 3,000US dollars per bottle. Since there are no generic versions of the drug yet, patients need to obtain it through formal channels, and the cost is relatively high.

In terms of drug purchase channels, patients can purchase isatuximab at hospital pharmacies with tumor drug qualifications. Before use, it needs to be evaluated by a doctor to confirm the indications and issue a prescription. During the entire treatment process, patients should strictly follow the doctor's instructions to complete the course of treatment, and regularly monitor blood routine, liver and kidney function and other indicators to ensure the safety of medication and observe the efficacy.

Keyword tags: isatuximab, multiple myeloma,CD38targeting, price, medical insurance

Reference materials:https://pmc.ncbi.nlm.nih.gov/articles/PMC8497289/